NovoCure Announces Publication Of Data Analysis From Phase 3 PANOVA-3 Trial

Benzinga · 17h ago

Novocure (NASDAQ:NVCR) announced today that JAMA Network Open published the results of the prespecified secondary analysis of data from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy concomitant with gemcitabine and nab-paclitaxel in patients with unresectable, locally advanced pancreatic adenocarcinoma.